TET2 and leukemia: The leukemias were transplantable into secondary recipients, and the shorter latency of the TET2-deficient CebpaDM AML was preserved in this setting (Supplemental Fig. 2h–i), indicating that TET2 not only has important tumor suppressive functions during malignant transformation but also during progression of AML.